Boehringer buys NBE for €1.18bn, adding cancer ADC expertiseBoehringer Ingelheim has expanded its oncology focus for the second time this week by buying Swiss biotech NBE-Therapeutics, Share XBoehringer buys NBE for €1.18bn, adding cancer ADC expertisehttps://pharmaphorum.com/news/boehringer-buys-nbe-for-e1-18bn-adding-cancer-adc-expertise/
FDA sets May date for verdict on ADC’s lymphoma drug LoncaADC Therapeutics could claim its first product approval in the US next May, after the FDA started a Share XFDA sets May date for verdict on ADC’s lymphoma drug Loncahttps://pharmaphorum.com/news/fda-sets-may-date-for-verdict-on-adcs-lymphoma-drug-lonca/
Exelixis doubles down on ADCs for cancer with NBE, Catalent dealsExelixis made its name developing small-molecule drugs for cancer, so a new pair of deals focused on antibody-drug Share XExelixis doubles down on ADCs for cancer with NBE, Catalent dealshttps://pharmaphorum.com/news/exelixis-doubles-down-on-adcs-for-cancer-with-nbe-catalent-deals/
FDA reviewer warns of eye trouble with GSK’s myeloma ADCGlaxoSmithKline heads for an FDA advisory committee meeting this week for belantamab mafodotin – its much-touted treatment for Share XFDA reviewer warns of eye trouble with GSK’s myeloma ADChttps://pharmaphorum.com/news/fda-reviewer-warns-of-eye-trouble-with-gsks-myeloma-adc/
FDA starts quick review of Astellas/Seattle Genetics’ bladder cancer drugThe FDA has started a priority review of Seattle Genetics and Astellas’ antibody-drug conjugate enfortumab vedotin in bladder Share XFDA starts quick review of Astellas/Seattle Genetics’ bladder cancer drughttps://pharmaphorum.com/news/fda-starts-quick-review-of-astellas-seattle-genetics-bladder-cancer-drug/
Denmark’s Genmab raises a bumper $500m-plus in Nasdaq IPOGenmab has shattered recent records with its Nasdaq listing, raising $506 million to help it advance multiple antibody Share XDenmark’s Genmab raises a bumper $500m-plus in Nasdaq IPOhttps://pharmaphorum.com/news/denmarks-genmab-raises-a-bumper-500m-plus-in-nasdaq-ipo/